# Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation

Study · id `cardio:ct-nct03373461` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03373461](<https://clinicaltrials.gov/study/NCT03373461>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT03373461

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

## Technical summary

Registry record NCT03373461. Randomized; double masking; primary purpose treatment. Start 2018-02-07 (actual); primary completion 2020-12-29 (actual). Results posted on 2022-10-07.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT03373461, source copy `cardio:ctgov-nct03373461-2023-01-30`, retrieved 2026-10-31)
- Started: 2018-02-07 (actual) (ClinicalTrials.gov record NCT03373461, source copy `cardio:ctgov-nct03373461-2023-01-30`, retrieved 2026-10-31)
- Primary completion: 2020-12-29 (actual) (ClinicalTrials.gov record NCT03373461, source copy `cardio:ctgov-nct03373461-2023-01-30`, retrieved 2026-10-31)
- Completion: 2021-06-22 (actual) (ClinicalTrials.gov record NCT03373461, source copy `cardio:ctgov-nct03373461-2023-01-30`, retrieved 2026-10-31)
- Results first posted: 2022-10-07 (ClinicalTrials.gov record NCT03373461, source copy `cardio:ctgov-nct03373461-2023-01-30`, retrieved 2026-10-31)
- Countries: Argentina; Australia; Belgium; Brazil; China; Colombia; Czechia; Denmark; Finland; France; Germany; Hong Kong SAR China; India; Israel; Japan; Malaysia; Netherlands; Norway; Singapore; South Korea; Sweden; Taiwan; Thailand; Türkiye; United Kingdom (ClinicalTrials.gov record NCT03373461, source copy `cardio:ctgov-nct03373461-2023-01-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03373461-2023-01-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
- Condition: IgA Nephropathy
- Intervention (Drug): LNP023
- Intervention (Other): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: f5d8f2d6bfa620cef63bb560143566f5a7ab7b913005229f4d62595ab776b2bf
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
